Climb Bio, Inc.
CLYMNasdaq
$12.70
↑ +1.0%Jul 17 close · end-of-day
Price
1Y↑ +807.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$866.2M
Enterprise Value
$756.7M
P/E
—
P/S
—
P/B
5.8
EV/EBITDA
—
PEG
—
FCF Yield
-6.3%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$52.8M
Free Cash Flow (TTM)
-$54.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-35.6%
ROIC
-123.2%
Debt / Equity
—
Net Cash
$109.6M
Return 1Y
+769.9%
Company profile
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
- CEO
- Aoife M. Brennan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9
- Headquarters
- Massachusetts
- Website
- climbbio.com
Management & directors
- Brennan AoifePresident and CEO
- Pimblett EmilySVP, Finance & CAO
Roles derived from SEC Form 4 filings.
Earnings
CLYM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.20↓ -35.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$20.9M | -$35.7M | -$45.1M | -$40.3M | -$82.0M | -$67.9M |
| Net income | -$20.7M | -$47.5M | -$45.2M | -$35.1M | -$73.9M | -$59.9M |
| Diluted EPS | — | -$4.24 | -$1.72 | -$1.30 | -$1.53 | -$0.88 |
| Operating cash flow | -$14.1M | -$36.1M | -$37.4M | -$20.6M | -$15.6M | -$54.4M |
| Free cash flow | — | — | — | — | -$15.6M | -$54.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$56.4M | -$11.7M | -$10.9M | -$23.0M | -$10.7M | -$14.9M | -$19.3M | -$15.2M |
| Net income | -$54.9M | -$8.9M | -$8.4M | -$20.8M | -$8.7M | -$12.9M | -$17.5M | -$13.7M |
| Diluted EPS | -$1.81 | -$0.13 | $0.47 | -$0.31 | -$0.13 | -$0.19 | -$0.25 | -$0.20 |
| Operating cash flow | -$667,000.00 | -$7.6M | -$5.5M | -$15.4M | -$11.1M | -$12.1M | -$15.6M | -$14.4M |
| Free cash flow | — | -$7.6M | — | — | — | -$12.2M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-29 | Brennan Aoife· President and CEO | Sale | 30,902 | $13.17 | $406,979.34 | filing |
| 2026-06-27 | Brennan Aoife· President and CEO | Option exercise | 68,750 | — | — | filing |
| 2026-02-26 | Thomas Stephen Basil | Sale | 16,313 | $7.01 | $114,288.88 | filing |
| 2026-02-25 | Thomas Stephen Basil | Sale | 33,687 | $7.00 | $235,963.96 | filing |
| 2026-02-13 | Thomas Stephen Basil | Sale | 10,000 | $5.81 | $58,141.00 | filing |
| 2026-02-12 | Thomas Stephen Basil | Sale | 90,000 | $5.23 | $470,988.00 | filing |
| 2026-01-05 | RA CAPITAL MANAGEMENT, LLC | Buy | 7,111 | $3.50 | $24,888.50 | filing |
| 2025-12-12 | RA CAPITAL MANAGEMENT, LLC | Buy | 101,462 | $2.86 | $290,181.32 | filing |
| 2025-12-11 | RA CAPITAL MANAGEMENT, LLC | Buy | 213,099 | $2.18 | $464,555.82 | filing |
| 2025-12-11 | RA CAPITAL MANAGEMENT, LLC | D | 20,440,000 | $0.00 | $0.00 | filing |
| 2025-08-07 | Thomas Stephen Basil | Award | 100,375 | $0.00 | $0.00 | filing |
| 2025-06-30 | Brennan Aoife· President and CEO | Sale | 20,618 | $1.22 | $25,153.96 | filing |
| 2025-06-27 | Brennan Aoife· President and CEO | Option exercise | 68,750 | — | — | filing |
| 2025-06-27 | Thomas Stephen Basil | Option exercise | 25,094 | — | — | filing |
| 2025-06-20 | Pimblett Emily· SVP, Finance & CAO | Sale | 1,242 | $1.24 | $1,540.08 | filing |
| 2025-06-18 | Pimblett Emily· SVP, Finance & CAO | Option exercise | 5,000 | — | — | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.